Your SheMed clinician can advise on whether your current dose is appropriate to maintain or whether moving up is likely to add meaningful benefit
The long-term safety and efficacy of semaglutide for HS patients still need to be thoroughly evaluated
We need to make patients more aware that this option is available for them, she said
Some GLP-1 agonists (particularly semaglutide) carry warnings about diabetic retinopathy complications
4e, f) were cultured in uridine-supplemented media to prevent them from undergoing ferroptosis-independent cell death, as previously published 19
Therefore, this class of medications should not be withheld for this reason, especially given the significant glycemic, cardiovascular, and weight loss effects